Peter Lichtlen is the Chief Medical Officer at Sucampo Pharmaceuticals Inc. a Nasdaq-listed biopharmaceutical company located in Bethesda (USA), Zug (Switzerland) and Osaka (Japan). In his role he oversees both clinical development and Medical Affairs of the company’s pipeline projects and product portfolio on a global basis. He also has a leading role in the company’s interactions with regulatory agencies across the globe related to CTAs/INDs and marketing authorization applications. He has also successfully managed reimbursement negotiations with reimbursement agencies such as UK NICE. Prior to joining Sucampo, Peter held various roles of increasing responsibility at ESBATech AG (acquired by Alcon/Novartis in 2009), of Schlieren, Switzerland, which he joined in 2000. At ESBATech, Peter served as Medical Director/Head, Clinical Research and Development, and a member of its senior management team, from 2004 to 2010. Peter’s focus in terms of pharmaceutical product development has been in ophthalmology, gastrointestinal diseases and rheumatology, with exposure to projects in other therapeutic areas as well.
Peter also co-founded Numab AG, a Swiss biotechnology company that innovates antibody-based therapeutics, where he also serves a member of the Board of Directors. Peter is a member of the Swiss Medical Association (FMH) and the Swiss Association of Pharmaceutical Professionals (SwAPP), the author of various peer-reviewed articles, and the holder of several patents. Peter earned doctorate degrees in medicine and molecular biology at the University of Zurich and holds a bachelor degree in business administration.”